We transform healthcare through the delivery of digital therapeutics to people with long-term conditions

Our services are used by more than 70,000 patients in the UK. Available via prescription only, Mapmyhealth helps healthcare providers tackle long-term conditions in the most engaging, effective and scalable way possible.

Our Approach

mmd-logo

Mapmydiabetes® is the only NICE endorsed diabetes self-management and collaborative care service, fully integrated with usual care.

"Mapmydiabetes has literally changed my life, I’ve lost weight, my blood sugars are down. It allows me to have the discussions with my Practice on an equal footing – I feel so much more in control."

Mapmydiabetes Patient, UK

 

“In 10 years, healthcare providers will prescribe digital medicine more often than they prescribe pharmaceuticals or biologics.”

 Ryan Rossier, 2016

Where Mapmyhealth sits in the digital health universe*

Single Use mHealth

Focuses on a single purpose for a single user, typically consumer initiated.

Smartphone apps and wearable tech products that support the user to record data which may be communicated to others. Consumer driven, focus on wellness, diet and exercise.

Social mHealth

Draws upon the support and encouragement provided through social networks.

Gamification and competition based apps which encourage users to meet goals. Consumers more likely to pursue activities independently.

Integrated mHealth

Links apps and devices with the formal healthcare system.

Mobile technology linking patients and HCPs.

Tailored to multiple end users; consumers, physicians and administrators.

Complex mHealth

Leverages advanced integrated analytics for decision support.

Predictive analytics applied to complex daata generated through mHealth applications.

Focus on achieving optimal management of a specific disease.

*Derived from Deloitte US Center for Health Solutions, 2016

Our Approach

SCALABLE & ACCESSIBLE SERVICES

1

We collaborate with world-leading academic and clinical experts, patients and family members. Together we develop beautiful, easy-to-use, evidence-based, disease-specific digital therapeutics.

2

Validated clinically, our products are continuously improved to meet the needs of our users and customers.

3

We excel in implementing at pace and scale in the NHS. Our proprietary SHeRPaTM Implementation program, ensures our products become part of usual care.

4

We demonstrate the value of our approach by gathering clinical trial and real-world data, answering the questions of patients, clinicians and payors.

Technology enabled care services

Awards for Innovation & Excellence

Development Pipeline

FROM CONCEPT THROUGH TO MARKET

 
Concept
Development
Clinical Validation
Market

Mapmydiabetes ®

The only NICE endorsed online support program for patients with type 2 diabetes, Mapmydiabetes is in use across the NHS, improving the knowledge, self-management skills and outcomes of those with diabetes.

  • 100%

ASIO ®

A scalable weight-loss program, providing round-the-clock support to patients losing weight in specific, high-need circumstances.

  • 60%

SurvivorMap™

Ensuring that those living with, and beyond cancer, get the care and support they need to lead as healthy and active a life as possible.

  • 50%

SkinMap™

Supporting patients and healthcare professionals to achieve the best outcomes in the management of long-term skin conditions.

  • 25%

MyHealth Engine™

The proprietary platform underpinning our world-leading digital therapeutics, the MyHealth Engine offers limitless scalability and versatility. This highly secure environment, supports broad interoperability with third party applications and devices and accommodates very large user numbers.

  • 100%

“The MedTech industry has met its next growth engine – mHealth. By harnessing the exponential power of mobile technologies, data and analytics, mHealth is anticipated to disrupt traditional health care delivery models and drive innovation across the care continuum.”

Mobilizing MedTech for mHealth – Market trends and potential opportunities, Deloitte July 2015

About

Mapmyhealth is a UK-based healthcare company established in response to the overwhelming global threat of long-term conditions.

We deliver digital therapeutics that are embedded into usual care pathways to help healthcare providers tackle long-term conditions in the most engaging, effective and scalable way possible.

Our globally-reproducible approach addresses the really big challenges of healthcare delivery for long-term conditions both now, and in the future.

Technology is revolutionising healthcare, and the way it’s delivered. We’re already delivering our digital therapeutics to tens of thousands of patients across the UK and beyond – and watching in real-time at the effects this can have on patient health and wellbeing.

Dr. Matthew Goodman - Medical Director

Working Together

Accreditations & Endorsements

Our Latest Press

August 3, 2016

Diabetic prescriptions now costing the NHS £1Bn a year

The escalating diabetes crisis is now costing the NHS almost £1 billion a year in prescriptions to treat and manage the disease. Total spending spiralled by […]
July 14, 2016

Diabetes treatment ‘inextricably’ linked to patient education

The successful treatment of type 2 diabetes is inextricably linked to how well patients understand their own role in managing the disease, according to a new […]
June 21, 2016

Diabetes Digital Coach: Putting patients in the driving seat

Elizabeth Dymond, deputy enterprise director at the West of England Academic Health Science Network (AHSN), talks about Diabetes Digital Coach, an NHS-based Internet of Things (IoT) […]

“First-in-class, best-in-class”

NHS South East CSU, Competitor Horizon Analysis 2016
Working Together

Our Partners

Contact us


Please leave this field empty.